Advertisement

Immune Systems Rather than Antigenic Epitopes Elicit and Produce Protective Antibodies Against HIV

  • Marc H V Van Regenmortel
Chapter

Abstract

It is common parlance to refer to viral antigens and their epitopes as immunogens capable of producing antibodies (Abs) against the virus that harbours them. Words have an insiduous capacity to fashion our thinking and terms like immunogen and immunogenicity do suggest that epitopes are able to generate immune responses, although they only trigger in the host a series of reactions with B-cell receptors that eventually leads to the immune system (IS) producing a variety of antibodies. Although everyone in the field is well aware that antigens are different from immunogens, it seems that in many cases investigators do not use appropriate experimental tools for studying and controlling the immunogenicity of proteins rather than their antigenicity.

References

  1. Berzofsky JA. Intrinsic and extrinsic factors in protein antigenic structure. Science. 1985;229:932–40.PubMedGoogle Scholar
  2. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature’s pathways. Immunol Rev. 2013;254:225–44.CrossRefGoogle Scholar
  3. Pejchal R, Wilson IA. Structure-based vaccine design in HIV: blind men and the elephant? Curr Pharm Des. 2010;16:3744–53.CrossRefGoogle Scholar
  4. Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A. 2010;107:1529–34.CrossRefGoogle Scholar
  5. Stamatatos L, Pancera M, McGuire AT. Germline-targeting immunogens. Immunol Rev. 2017;275:203–16.CrossRefGoogle Scholar
  6. Tomaras GD, Plotkin SA. Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol Rev. 2017;275:245–61.CrossRefGoogle Scholar
  7. Van Regenmortel MHV. Two meanings of reverse vaccinology and the empirical nature of vaccine science. Vaccine. 2011a;29:7875.CrossRefGoogle Scholar
  8. Van Regenmortel MHV. Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol. 2012b;3:194.  https://doi.org/10.3389/fimmu.2012.00194.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Van Regenmortel MHV. Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J Mol Recognit. 2014a;27:627–39.CrossRefGoogle Scholar
  10. Van Regenmortel MHV. An outdated notion of antibody specificity is one of the major detrimental assumptions of the structure-based reverse vaccinology paradigm, which prevented it from developing an effective HIV-1 vaccine. Front Immunol. 2014b;5:593.  https://doi.org/10.3389/fimmu.1014.00593.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Van Regenmortel MHV. Structure-based reverse vaccinology failed in the case of HIV because it disregarded accepted immunological theory. Int J Mol Sci. 2016b;17:1591–625.  https://doi.org/10.3390/ijms17091591.CrossRefPubMedCentralGoogle Scholar
  12. Verkoczy L, Alt FW, Tian M. Human Ig knocking mice to study the development and regulation of broadly neutralizing antibodies. Immunol Rev. 2017;275:89–107.CrossRefGoogle Scholar
  13. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, Zhang MY, Longo NS, Dimitrov DS. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun. 2009;390:404–9.CrossRefGoogle Scholar
  14. Yu L, Guan Y. Immunologic basis for long HCDR3s in broadly neutralizing antibodies against HIV-1. Front Immunol. 2014;5:250.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Marc H V Van Regenmortel
    • 1
  1. 1.School of BiotechnologyUniversity of StrasbourgIllkirchFrance

Personalised recommendations